Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart cafraglutide; ...
Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Somer G. Anderson is CPA, doctor of accounting, and an accounting and finance professor who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback